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Abstract
Background: The TCF7L2 transcription factor is linked to a variety of human diseases, including type 2 diabetes
and cancer. One mechanism by which TCF7L2 could influence expression of genes involved in diverse diseases is
by binding to distinct regulatory regions in different tissues. To test this hypothesis, we performed ChIP-seq for
TCF7L2 in six human cell lines.
Results: We identified 116,000 non-redundant TCF7L2 binding sites, with only 1,864 sites common to the six cell
lines. Using ChIP-seq, we showed that many genomic regions that are marked by both H3K4me1 and H3K27Ac are
also bound by TCF7L2, suggesting that TCF7L2 plays a critical role in enhancer activity. Bioinformatic analysis of the
cell type-specific TCF7L2 binding sites revealed enrichment for multiple transcription factors, including HNF4alpha
and FOXA2 motifs in HepG2 cells and the GATA3 motif in MCF7 cells. ChIP-seq analysis revealed that TCF7L2 co-
localizes with HNF4alpha and FOXA2 in HepG2 cells and with GATA3 in MCF7 cells. Interestingly, in MCF7 cells the
TCF7L2 motif is enriched in most TCF7L2 sites but is not enriched in the sites bound by both GATA3 and TCF7L2.
This analysis suggested that GATA3 might tether TCF7L2 to the genome at these sites. To test this hypothesis, we
depleted GATA3 in MCF7 cells and showed that TCF7L2 binding was lost at a subset of sites. RNA-seq analysis
suggested that TCF7L2 represses transcription when tethered to the genome via GATA3.
Conclusions: Our studies demonstrate a novel relationship between GATA3 and TCF7L2, and reveal important
insights into TCF7L2-mediated gene regulation.
Background
The TCF7L2 (transcription factor 7-like 2) gene encodes a
high mobility group box-containing transcription factor
that is highly up-regulated in several types of human can-
cer, such as colon, liver, breast, and pancreatic cancer
[1-4]. Although TCF7L2 is sometimes called TCF4, there
is a helix-loop-helix transcription factor that has been
given the official gene name of TCF4 and it is important,
therefore, to be aware of possible confusion in the litera-
ture. Numerous studies have shown that TCF7L2 is an
important component of the WNT pathway [3,5,6].
TCF7L2 mediates the downstream effects of WNT signal-
ing via its interaction with CTNNB1 (beta-catenin) and it
can function as an activator or a repressor, depending on
the availability of CTNNB1 in the nucleus. For example,
TCF7L2 can associate with the members of the Groucho
repressor family in the absence of CTNNB1. The WNT
pathway is often constitutively activated in cancers, leading
to increased levels of nuclear CTNNB1 and up-regulation
of TCF7L2 target genes [3]. In addition to being linked to
neoplastic transformation, variants in TCF7L2 are thought
to be the most critical risk factors for type 2 diabetes
[7-10]. However, the functional role of TCF7L2 in these
diseases remains unclear. One hypothesis is that TCF7L2
regulates its downstream target genes in a tissue-specific
manner, with a different cohort of target genes being
turned on or off by TCF7L2 in each cell type. One way to
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test this hypothesis is to identify TCF7L2 target genes in a
diverse set of cell types.
Previous studies have used genome-wide approaches to
identify TCF7L2 target genes in human colon cancer cells
[11,12] and, more recently, chromatin immunoprecipita-
tion sequencing (ChIP-seq) analysis of TCF7L2 was
reported in hematopoietic cells [13]. In addition, TCF7L2
binding has been studied in rat islets and rat hepatocytes
[14,15]. However, to date no one study has performed
comparative analyses of genome-wide binding patterns of
TCF7L2 in diverse human cell types. We have now con-
ducted ChIP-seq experiments and comprehensively
mapped TCF7L2 binding loci in six human cell lines. We
identified datasets of common and cell-specific TCF7L2
binding loci and a set of predicted TCF7L2-regulated
enhancers (by comparing the TCF7L2 peak locations with
ChIP-seq data for the active enhancer marks H3K4me1
(histone H3 monomethylated on lysine 4) and H3K27Ac
(histone H3 acetylated on lysine 27)). We also predicted
bioinformatically and confirmed experimentally that
TCF7L2 co-localizes with cell type-specific factors. Finally,
we showed that GATA3 (GATA binding protein 3), which
co-localizes with TCF7L2 in MCF7 breast cancer cells, is
required for recruitment of TCF7L2 to a subset of binding
sites. Our studies reveal new insights into TCF7L2-
mediated gene regulation and suggest that cooperation
with other factors dictates different roles for TCF7L2 in
different tissues.
Results
Defining TCF7L2 genomic binding patterns
To identify TCF7L2 binding loci in a comprehensive man-
ner, we performed ChIP-seq using an antibody to TCF7L2
and profiled six human cell types, including colorectal car-
cinoma cells (HCT116), hepatocellular carcinoma cells
(HepG2), embryonic kidney cells (HEK293), mammary
gland adenocarcinoma cells (MCF7), cervical carcinoma
cells (HeLa), and pancreatic carcinoma cells (PANC1). We
chose these particular cell lines because TCF7L2 has been
associated with these types of cancers and because all of
these cells have various data sets associated with them as
part of the ENCODE project. The TCF7L2 gene has 17
exons, including 5 exons that are alternatively spliced in
different tissues [2,16-20]. Alternative splicing produces
two major isoforms of TCF7L2 in most cells, a cluster of
isoforms of approximately 79 kDa and a cluster of iso-
forms of approximately 58 kDa. All of these isoforms con-
tain the DNA binding domain, the CTNNB1 binding
domain, the Groucho binding domain, and the nuclear
localization signal. However, the CtBP (C-terminal binding
protein) binding domain is encoded at the carboxyl termi-
nus and is missing in the 58 kDa isoform [21,22]. The two
major isoforms are found at similar ratios in the six cell
lines that we analyzed (Additional file 1). For all cell types,
we performed duplicate ChIP-seq assays using chromatin
from two different cell culture dates (see Additional file 2
for details concerning all ChIP-seq experiments and infor-
mation on how to access the data). To ensure that our
data were of high quality and reproducible, we called
peaks [11,23,24] and then compared the peak sets using
the ENCODE overlap rules (Additional file 3); all datasets
had a high degree of reproducibility (Additional file 4). We
next combined the reads for each replicate experiment
and called TCF7L2 peaks for each cell type, identifying
tens of thousands of peaks in each cell type (Table 1; see
Additional file 5 for lists of all TCF7L2 binding sites in
each cell type and Additional file 6 for a summary of the
peak characteristics for each cell type). We used a satura-
tion analysis strategy (Additional file 3) to demonstrate
that the depth of sequencing of the ChIP samples was suf-
ficient to identify the majority of TC7L2 binding sites in
each cell type (Additional file 7).
We next determined if the TCF7L2 binding sites identified
in each cell type are unique to that cell type or if TCF7L2
binds to the same locations in different cells. We first per-
formed two-way comparisons of the peaks from all six cell
types and found that the overlaps ranged from a low of
18% of HepG2 sites being present in the HEK293 peak set
to a high of 46% of the HCT116 sites being present in the
PANC1 peak set. These low overlaps suggested that each
cell type contributes a unique set of peaks. To demon-
strate the cell type specificity of binding of TCF7L2, the
top 500 binding sites were selected from the ChIP-seq
datasets from each of the 6 cell types (a total of 3,000
peaks). Then, the sequenced tags in all 6 datasets corre-
sponding to the genomic regions spanning ±3 kb from the
center of each of the combined 3,000 peaks were clustered
with respect to these genomic regions (Figure 1). This
analysis demonstrates a clear cell type-specificity in the
Table 1 TCF7L2 binding sites and target genes
Total peaks Nearest genes Peaks per gene
HCT116 30,259 10,910 2.8
HEK293 24,457 6,254 3.9
HepG2 27,912 7,899 3.5
MCF7 27,721 6,934 4.0
HeLa 52,810 11,334 4.7
PANC1 31,744 9,438 3.4
Common 1,864 1,287 1.4
Total unique 116,270 14,193 8.2
Peaks were called using the BELT program on the merged duplicate datasets
for each cell type. Reported as the ‘Total peaks’ is the total number of TCF7L2
binding sites in each cell line, as well as the total number of unique peaks
when all six cell lines are considered together and the peaks identified as
being common to all six cell lines. To determine the number of ‘Nearest
genes’, the RefSeq gene nearest each TCF7L2 binding site was identified and
duplicates were removed (since TCF7L2 has multiple binding sites near many
genes), and the resultant number is indicated as the total number of target
genes for that peak set.
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top-ranked TCF7L2 binding sites. We note that one char-
acteristic of cancer cell lines is that they often have exten-
sive genomic amplifications. Peak calling programs (such
as the ones used in our analyses) that use input DNA
from the specific cancer cell can help to prevent many
false positive peaks that would otherwise rise to the top of
the peak list due to the fact that the amplified regions are
‘over-sequenced’ in comparison to the rest of the genome.
However, it is difficult to completely account for amplifi-
cations. Therefore, to ensure that the cell type specificity
that we observed was not due to TCF7L2 peaks in ampli-
fied regions, we used our peak-calling program Sole-search
to identify all genomic amplifications in the six cancer cell
lines (Additional file 8). Then, we identified the TCF7L2
peaks that are in the amplified regions in each cell line
(Additional file 9); all peaks from amplified regions were
removed from the peak lists prior to the analysis shown in
Figure 1. In total, we found that each cell type had more
than 10,000 TCF7L2 binding sites that were not found in
any of the sets of called peaks for the other 5 cell types
(see Additional file 10 for lists of cell type-specific TCF7L2
binding sites). Of course, it is possible that some sites that
appear to be cell type-specific are actually very small peaks
in another cell type and fall below the cutoff used in our
Figure 1 ChIP-seq analysis of TCF7L2 in six different human cell lines. Shown is the distribution of TCF7L2 binding within ±3 kb windows
around distinct genomic regions (n = 3,000) bound by TCF7L2 in a given cell type. ChIP-seq tags for each cell line were each aligned with
respect to the center of the combined top 500 peaks from each dataset and clustered by genomic position.
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analyses. Overall, we identified 116,270 non-redundant
TCF7L2 binding sites when the datasets from all 6 cell
lines are combined. Only 1,864 TCF7L2 binding loci were
common to all 6 cell lines, suggesting that TCF7L2 may
play an important, yet distinct, role in different cells.
To confirm the cell-specific TCF7L2 binding loci that
we observed in the ChIP-seq data, we chose a set of three
targets identified to be cell type-specific for each of the
six cell lines, three common targets, and three negative
regions not bound by TCF7L2 in any cell line and per-
formed quantitative ChIP-PCR (ChIP-qPCR) using DNA
isolated from ChIP samples that were distinct from the
samples used for ChIP-seq (Additional file 11). The com-
mon targets were bound by TCF7L2 in all samples,
whereas the negative controls showed very low enrich-
ment in all samples. In general, regions identified as cell
type-specific showed the greatest enrichment for TCF7L2
binding in that corresponding cell line (for example, the
PANC1-specific sites showed very high enrichment in
ChIP samples from PANC1 cells, low enrichment in sam-
ples from HepG2, HeLa, and HCT116 cells, and no
enrichment in samples from HEK293 or MCF7 cells).
Thus, ChIP-qPCR confirms the specificity of targets iden-
tified in the ChIP-seq data in each cell line. Examples of
common and cell type-specific TCF7L2 binding sites are
shown in Figure 2.
To determine the potential set of genes regulated by
TCF7L2 in each cell type, we identified the closest
annotated gene to each TCF7L2 binding site in the six
different cell types and the closest annotated gene to the
set of 1,864 common TCF7L2 binding sites. The num-
ber of target genes (as defined by the nearest gene to a
TCF7L2 binding site) ranged from approximately 6,000
to 11,000 in the different cell lines (Table 1). In addi-
tion, we also observed that the number of target genes
in each cell line was considerably less than the number
of TCF7L2 binding sites, demonstrating that TC7L2
binds to multiple locations near each target gene (Table
1). Although less than 2% (1,864 of 116,270 peaks) of
the total number of peaks were commonly bound by
TCF7L2 in all 6 cell lines, 9% of target genes were com-
mon to all 6 cell lines (1,287 of 14,193 genes). This indi-
cates that TCF7L2 regulates certain genes in different
cell types using different binding sites. For example,
there are 12 TCF7L2 binding sites near the SH3BP4
gene, but these sites are different in MCF7, HCT116,
and PANC1 cells (Figure 2c).
The binding patterns shown in Figure 2c indicate that
TCF7L2 does not necessarily bind to promoter regions,
but rather binds to a variety of genomic locations near or
within the SH3BP4 locus. To evaluate the global distribu-
tion of TCF7L2 binding loci in each cell line, we plotted
the percentage of TCF7L2 sites versus their distance to
the nearest transcription start site. Even though TCF7L2
binds to different sites in the different cell lines, the trend
for the distribution of TCF7L2 target loci is the same for
each cell line (Figure 3a). Although some of the TCF7L2
binding sites are within 1 kb of a transcription start site,
most of the sites are located at distances greater than 10
kb from a start site. However, we did find that the com-
mon sites to which TCF7L2 is bound in all six cell lines
are more enriched near the 5’ of a gene than are the
other sites (Figure 3a). A detailed analysis of the TCF7L2
binding sites, including the location of each site relative
to the transcription start site of the nearest gene for all
peaks in each of the six cell lines can be found in Addi-
tional file 5.
TCF7L2 binds to enhancer regions
The fact that TCF7L2 can bind to regions far from core
promoters suggested that TCF7L2 might bind to enhan-
cers. Recent studies have shown that enhancers can be
identified by enrichment for both the H3K4me1 and
H3K27Ac marks [25-27]. To determine if the regions
bound by TCF7L2 are also bound by these modified his-
tones, we performed ChIP-seq experiments in PANC1,
HEK293, HCT116 and MCF7 cells using antibodies that
specifically recognize histone H3 only when it is mono-
methylated on lysine 4 or when it is acetylated on lysine
27; we also used H3K4me1 and H3K27Ac data for HeLa
and HepG2 cells from the ENCODE project. Duplicate
ChIP-seq experiments were performed using two different
cultures of cells for each cell type, peaks were called indivi-
dually to demonstrate reproducibility (Additional file 4),
the reads were merged and a final peak set for both
H3K4me1 and H3K27Ac was obtained. We then identified
predicted active enhancers as regions having both
H3K4me1 and H3K27Ac and determined the percentage
of the TCF7L2 sites that have either or both of the modi-
fied histones (Table 2). We found that, for most cells, the
majority of TCF7L2 sites co-localized with H3K4me1 and
H3K27Ac. However, a smaller percentage of the TCF7L2
sites in MCF7 cells co-localized with active enhancers.
Heatmaps of the tag density of the histone ChIP-seq
experiments for each cell line relative to the center of the
TCF7L2 peak locations are shown in Figure 3c. Although
most TCF7L2 binding sites show robust levels of both
marks, the TCF7L2 sites in MCF7 cells again show a smal-
ler percentage of sites having high levels of the modified
histones. To determine if the TCF7L2 binding sites in
MCF7 cells correspond to sites bound by histone modifi-
cations associated with transcriptional repression, we per-
formed duplicate ChIP-seq analysis using antibodies to
H3K9me3 (histone H3 trimethylated on lysine 9) and
H3K27me3 (histone H3 trimethylated on lysine 27); we
also used H3K4me3 (histone H3 trimethylated on lysine 4)
and RNA polymerase II ChIP-seq data from the ENCODE
project. As shown in Figure 3d, neither the proximal nor
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distal TCF7L2 binding sites show high levels of H3K9me3
or H3K27me3.
To further investigate the role of TCF7L2 in cell type-
specific enhancers, we determined the percentage of
active enhancers in each of the six cell types (that is,
genomic regions bound by both H3K4me1 and
H3K27Ac) that are also bound by TCF7L2. We found
that more than 40% of all enhancers in the different cell
lines are occupied by TCF7L2 (Figure 3b). These results
indicate that TCF7L2 ChIP-seq data identify many of
the active enhancers in a given cell type and suggest
that TCF7L2 may play a critical role in specifying the
transcriptome in a variety of cancer cells. An example of
TCF7L2 binding to sites marked by H3K4me1 and
H3K27Ac in HepG2 cells is shown in Additional file 12;
TCF7L2 does not bind to this same site in HeLa cells
and these sites are also not marked by the modified his-
tones in HeLa cells.
Motif analysis of genomic regions bound by TCF7L2
To investigate the predominant motifs enriched in
TCF7L2 binding sites, we applied a de novo motif discov-
ery program, ChIPMotifs [28,29], to the sets of TCF7L2
peaks in each cell type. We retrieved 300 bp for each loci
from the top 1,000 binding sites in each set of TCF7L2
peaks and identified the top represented 6-mer and 8-
mer (Additional file 13). For all cell lines, the same 6-mer
(CTTTGA) and 8-mer (CTTTGATC) motif was identi-
fied (except for HCT116 cells, for which the 8-mer was
CCTTTGAT). These sites are almost identical to the
Transfac binding motifs for TCF7L2 (TCF4-Q5:
SCTTTGAW) and for the highly related family member
LEF1 (LEF1-Q2:CTTTGA) and to experimentally discov-
ered motifs in previous TCF7L2 ChIP-chip and ChIP-seq
data [11,30]. These motifs are present in a large percen-
tage of the TCF7L2 binding sites. For example, more
than 80% of the top 1,000 peaks in each dataset from
Figure 2 Cell type-specific binding of TCF7L2. (a,b) The ChIP-seq binding patterns of TCF7L2 are compared in six cell lines, demonstrating
both common peaks (a) and cell type-specific binding (b). (c) The ChIP-seq binding patterns of TCF7L2 near and within the SH3BP4 locus is
shown for three cell lines. The number of tags reflecting the ChIP enrichments are plotted on the y-axis; the chromosomal coordinates (hg19)
shown are: (a) chr19:7,701,591-7,718,750; (b) chr1:112,997,195-113,019,766; and (c) chr2:235,767,270-235,974,731.
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each cell type contain the core TCF7L2 6-mer W1 motif,
with the percentage gradually dropping to approximately
50% of all peaks (Additional file 14).
Because the TCF7L2 motif is present in all the cell lines
at the same genomic locations, but TCF7L2 binds to
different subsets of the TCF7L2 motifs in the different
cell lines, this suggests that a cell type-specific factor may
help to recruit and/or stabilize TCF7L2 binding to speci-
fic sites in different cells. Also, as shown above, TCF7L2
binds to enhancer regions, which are typified by having
Figure 3 TCF7L2 binding sites are distal and enriched for active enhancer histone marks. (a) Shown for the TCF7L2 binding sites in the six
cell types and for the 1,864 peaks commonly bound in all six cells is the percentage of TCF7L2 binding sites in different genomic regions (hg19)
relative to the nearest transcription start site (TSS). (b) The percentage of active enhancer regions containing a TCF7L2 binding site; active
enhancers were defined by taking the regions that have an overlap of H3K4me1 and H3K27ac ChIP-seq peaks for the given cell line. (c) Heatmaps
of the ChIP-Seq tags for H3K27ac and H3K4me1 at TCF7L2-bound regions (±3 kb windows around the center of all TCF7L2 peaks) for each cell line
were generated by k-means cluster analysis. (d) The average RNA polymerase II and histone modification profiles of MCF7 cells are shown for the
±3 kb windows around the center of TCF7L2 peaks identified as proximal to RefSeq genes (upper graph) or distal to RefSeq genes (lower graph).
Table 2 TCF7L2 binds to enhancer regions
Cell
line
Percentage of TCF7L2 peaks at
H3K4me1 sites
Percentage of TCF7L2 peaks at
H3K27Ac sites
Percentage of TCF7L2 peaks at active enhancers
(H3K4me1 and H3K27Ac)
HCT116 68 72 57
HepG2 84 59 56
PANC1 63 74 55
HeLa 72 58 53
MCF7 34 46 25
TCF7L2 peaks were overlapped with called peaks for H3K27Ac or H3K4me1 or both H3K27Ac and H3K4me1 in the same cell line. The percentage of TCF7L2
peaks in each category is indicated.
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binding sites for multiple factors. To test the hypothesis
that TCF7L2 associates with different transcription factor
partners in different cell types, we identified motifs for
other known transcription factors using the program
HOMER [31]. For these analyses, we used the subset of
TCF7L2 binding sites that were specific to each of the six
different cell types. The top four significantly enriched
non-TCF7L2 motifs for each dataset are shown in Table
3; many of these motifs correspond to binding sites for
factors that are expressed in a cell type-enriched pattern.
To assess the specificity of the identified motifs with
respect to TCF7L2 binding, we chose one motif specific
to HepG2 TCF7L2 binding sites (hepatocyte nuclear fac-
tor (HNF)4a) and one motif specific to MCF7 TCF7L2
binding sites (GATA3) and plotted motif densities in the
HepG2 cell type-specific TCF7L2 peaks (Figure 4a) and
the MCF7 cell type-specific TCF7L2 peaks (Figure 4b). In
HepG2 cells, the HNF4a motif, but not the GATA3
motif, is highly enriched at the center of TCF7L2 binding
regions. In contrast, in MCF7 cells the GATA3 motif, but
not the HNF4a motif, is highly enriched at the center of
TCF7L2 binding regions.
TCF7L2 co-localizes with HNF4a and FOXA2 in HepG2
cells
To validate the co-localization of TCF7L2 with factors
binding to the identified motifs in HepG2 cells, we
obtained ChIP-seq data for HNF4a and FOXA2 (forkhead
box a2) from the ENCODE Consortium and overlapped
the peak sets with the set of TCF7L2 peaks specific for
HepG2 cells (Figure 5a). We found that approximately 50%
of all HepG2-unique TCF7L2 sites are shared by HNF4a
and FOXA2. The sites bound only by HNF4a, only by
TCF7L2, or by both factors were analyzed for enrichment
of the HNF4a and TCF7L2 motifs (Figure 5b). We found
that the motifs were only enriched in the set of peaks spe-
cifically bound by each factor. For example, the sites bound
only by TCF7L2 but not by HNF4a have TCF7L2 motifs
but do not have HNF4a motifs (and vice versa). However,
sites bound by both TCF7L2 and HNF4a have motifs for
both factors. These results indicate that the HNF4a motif
was not identified simply due to its sequence being similar
to the TCF7L2 motif and suggest that both factors bind
directly to the DNA at the co-localizing sites. We next
plotted the location of the experimentally determined
HNF4a and FOXA2 sequence tags relative to the center of
the TCF7L2 binding site in the set of 7,576 peaks bound
by all three factors. As shown in Figure 5c, both HNF4a
and FOXA2 localize near the center of the TCF7L2 bind-
ing sites. An example of the binding patterns of all three
factors at the GREB1 locus is shown in Figure 5d. These
results support the hypothesis that HNF4a and FOXA2
may be involved in specifying a portion of the binding of
TCF7L2 in liver cells.
GATA3 is required for TCF7L2 recruitment to a subset of
sites in MCF7 cells
We next examined the relationship between GATA3 and
TCF7L2 binding in MCF7 cells. We performed duplicate
ChIP-seq experiments for GATA3 in MCF7 cells, called
peaks, and then determined the overlap of GATA3 peaks
with the TCF7L2 peaks in MCF7 cells (Figure 6a). We
found that nearly half of all MCF7-unique TCF7L2 sites
are bound by GATA3 (49%); an example of the binding
patterns of both factors at the CDT1 locus is shown in
Figure 6a. The observation that two factors bind to the
same location in the genome could be a result of both fac-
tors binding to the same (or nearby) site at the same time
or could be due to one factor binding to the genomic
region in one cell with the other factor binding to that
same region in a different cell in the population. To
address these possibilities, we performed motif analyses,
co-immunoprecipitations, and knockdown experiments.
The sites bound only by GATA3, only by TCF7L2, or by
both factors were analyzed for the enrichment of the
GATA3 and TCF7L2 motifs (Figure 6b). We found that
the sites bound only by TCF7L2 contain the TCF7L2
motif but not the GATA3 motif and the sites bound only
by GATA3 contain the GATA3 motif but not the TCF7L2
motif. Interestingly, we found that sites bound by both
GATA3 and TCF7L2 are enriched for the GATA3 motif
but are not enriched for the TCF7L2 motif. These results
suggest that GATA3 may bind to the DNA and recruit
TCF7L2 to these sites. To determine if GATA3 can recruit
TCF7L2 to a GATA motif in the genome, we introduced
small interfering RNAs (siRNAs) specific for GATA3 into
MCF7 cells and then tested binding of TCF7L2 to sites
bound by both TCF7L2 and GATA3 and to sites bound
only by TCF7L2. We found that depletion of GATA3
resulted in the reduction of binding of TCF7L2 at the sites
normally bound by both factors but not at the TCF7L2
sites that are not bound by GATA3 (Figure 6c, left panel).
In contrast, knockdown of TCF7L2 reduced binding of
TCF7L2 but did not reduce binding of GATA3 (Figure 6c,
right panel). Thus, GATA3 is necessary for recruiting
Table 3 TCF7L2 cell type-specific modules
Cell line Top four co-localized motifs
HCT116 AP1, CTCF, NF-E2, SP1
HEK293 HOXC9, CDX2, PDX1, FOXA1
HepG2 HNF4a, FOXA2, ERRa, PPARg
HeLa-S3 ERG, MAZ, CEBP, NF-E2
MCF7 GATA3, AP2, TEAD, AP1
PANC1 CDX2, FOXA1, TEAD, RUNX2
The sets of TCF7L2 binding sites specific for each cell line (not found in any of
the other five cell lines) were analyzed using HOMER. The top four most
highly enriched motifs (as determined by P-value), not including the TCF7L2
motif, are shown for each cell line.
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TCF7L2 to a subset of its genomic binding sites in MCF7
cells but TCF7L2 is not necessary for GATA3 binding to
those same sites. We also performed sequential ChIP
assays (a TCF7L2 ChIP followed by a GATA3 ChIP and a
GATA3 ChIP followed by a TCF7L2 ChIP) to address
whether both TCF7L2 and GATA3 are on the same DNA
fragments (Additional file 15). In both cases, the sites
bound by both TCF7L2 and GATA3 could be enriched by
Figure 4 Association of other motifs with TCF7L2 binding sites. (a,b) TCF7L2 binding sites unique to HepG2 cells (a) or MCF7 cells (b) were
analyzed for the indicated motifs; the position of each motif is plotted relative to the center of the TCF7L2 binding site.
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Figure 5 Association of TCF7L2 and HNF4a in HepG2 cells. (a) HNF4a and FOXA2 ChIP-seq data were downloaded from the UCSC genome
browser, and peaks were called and overlapped with the HepG2 cell type-specific TCF7L2 peaks. (b) Peaks bound only by HNF4a, only by
TCF7L2, or by both factors were analyzed for the presence of HNF4a and TCF7L2 motifs. (c) For the set of 7,576 peaks bound by all three
factors, the location of the HNF4a and FOXA2 peaks were plotted relative to the center of the TCF7L2 peak. (d) A comparison of TCF7L2,
HNF4a, and FOXA2 binding patterns near the GREB1 locus is shown. The hg19 genomic coordinates are chr2:11,636,208-11,708,654. The number
of tags reflecting the ChIP enrichments is plotted on the y-axis.
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Figure 6 Association of TCF7L2 and GATA3 in MCF7 cells. (a) GATA3 ChIP-seq in MCF7 cells was performed, and peaks were called and
then overlapped with the MCF7 cell type-specific TCF7L2 peaks; a comparison of TCF7L2 and GATA3 binding patterns near the CDT1 locus is
shown. The hg19 genomic coordinates are chr16:88,861,964-88,880,233. (b) Peaks bound only by GATA3, only by TCF7L2, or by both factors
were analyzed for the presence of GATA3 and TCF7L2 motifs. The GATA3 motif is found in sites bound by GATA3 only and in sites bound by
both factors, whereas the TCF7L2 motif is found only in the sites bound only by TCF7L2 and not in the sites bound by both factors. (c)
Depletion of GATA3 results in loss of TCF7L2 occupancy at sites bound by TCF7L2 and GATA3 sites but not at sites only bound by TCF7L2.
MCF7 cells were transfected with siRNAs specific for TCF7L2 or GATA3 or control siRNAs. ChIP-qPCR assays were performed using antibodies
specific for TCF7L2 (left panel) or GATA3 (right panel) using primers specific for peaks bound only by GATA3, only by TCF7L2, or by both factors.
Shown are ChIP-qPCR results performed in triplicate and plotted with the standard error of two independent experiments. (d) Co-
immunoprecipitation of endogenous GATA3 and FLAG-tagged TCF7L2 constructs from MCF7 cells. The left panel analyzes whole-cell extracts
(WCE) and FLAG immunoprecipitation (FLAG IP) eluates from MCF7 cells transfected with the indicated FLAG-tagged plasmids; the membrane
was incubated with both anti-FLAG and anti-GATA3 antibodies. Note that the GATA3 signal in input WCE extracts is quite weak and can
generally only be visualized after concentration by immunoprecipitation. The right panel is a separate blot prepared in the same way (using the
GATA antibody for immunoprecipitation), but does not include the WCE extracts. V, vector control; E, full length TCF7L2; EΔ, TCF7L2 lacking the
amino terminus; B, TCF7L2 isoform lacking the carboxyl terminus; BΔ, TCF7L2 isoform lacking the amino and carboxyl termini.
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the second antibody, supporting the hypothesis that the
two factors are binding at the same time to the same
region. To further investigate the hypothesis that GATA3
tethers TCF7L2 to the genome, we sought to determine
whether GATA3 interacts with TCF7L2 in MCF7 cell
extracts using co-immunoprecipitation. Accordingly, we
expressed in MCF7 cells several different FLAG-tagged
TCF7L2 constructs that lack either or both of the amino-
or carboxy-terminal regions. The amino-terminal region
of TCF7L2 mediates the interaction with b-catenin and
the carboxy-terminal portion contains the so-called ‘E-tail’
important for the association with various co-regulators,
including CREBBP/EP300 (CREB binding protein/E1A
binding protein p300) [32-34]. A predominant isoform
lacking the E-tail has been referred to as the B-isoform
[17]. Immunoprecipitation of full-length TCF7L2 (the E-
isoform) and the B-isoform (which lacks the E-tail) as well
as B and E isoforms lacking the amino-terminal b-catenin
binding domain (termed EΔ and BΔ) revealed that all iso-
forms are capable of co-precipitating GATA3 with equal
efficiency (Figure 6d). Conversely, immunoprecipitation of
GATA3 co-precipitated each of the tested TCF7L2 con-
structs, albeit with different degrees of efficiency (the full-
length E-tail TCF7L2 construct showed the greatest effi-
ciency of co-precipitation with GATA3). Importantly,
FLAG immunoprecipitation of extracts prepared from
MCF7 cells transfected with an empty vector failed to pre-
cipitate GATA3 and control IgG immunoprecipitation
reactions failed to precipitate GATA3 and the full-length
E construct. Therefore, endogenous GATA3 and exogen-
ously expressed TCF7L2 can interact in MCF7 cells.
Taken together, these data show that TCF7L2 and
GATA3 interact and co-localize to specific genomic loci
in MCF7 cells.
TCF7L2 functions as a repressor when tethered to the
genome by GATA3
To establish whether TCF7L2 and GATA3 have a co-
regulatory role in the expression of specific target genes,
we performed RNA-seq analysis of MCF7 cells before
and after knockdown of TCF7L2 or GATA3. We found
that the expression of 914 and 469 genes was significantly
changed compared to cells treated with control siRNA
for GATA3 or TCF7L2, respectively. Many of the genes
showing expression changes can be classified as having
functions involved in breast cancer, cell differentiation,
and response to hormone stimulus (Figure 7c); a list of
all genes whose expression was significantly altered by
each knockdown can be found in Additional file 16. To
identify genes that might be directly co-regulated by
GATA3 and TCF7L2, we first identified a set of 3,614
genes that are directly bound by both GATA3 and
TCF7L2 (Figure 7a). Then, we analyzed the expression of
these 3,614 GATA3+TCF7L2 target genes and found
that 268 and 163 genes have significantly altered expres-
sion levels in siGATA3- or siTCF7L2-treated cells,
respectively (Figure 7b). Approximately half of the set of
genes deregulated upon reduction of GATA3 show
increased expression and half show decreased expression,
suggesting that GATA3 can act as both an activator and
a repressor at the GATA3+TCF7L2 target genes. In con-
trast, most of the genes deregulated by reduction of
TCF7L2 show increased expression, suggesting that
TCF7L2 functions mainly as a repressor of the set of
genes co-bound by TCF7L2 and GATA3. As a final ana-
lysis, we identified genes that are co-bound by TCF7L2
and GATA3 and that show expression changes in both
the knockdown TCF7L2 cells and in the knockdown
GATA3 cells. Although this is a small set of genes, they
mainly clustered into two categories. For example, 16 co-
bound genes showed an increase in expression in both
the TCF7L2 and GATA3 knockdown cells, indicating
that both factors were functioning as a repressor of these
genes. In addition, we identified ten genes that decreased
with GATA3 knockdown but increased upon TCF7L2
knockdown, suggesting that TCF7L2 functioned to nega-
tively modulate GATA3-mediated activation at these
genes. A list of the genes that are cooperatively repressed
by direct binding of TCF7L2 and GATA3 and a list of
genes for which recruitment of TCF7L2 antagonizes
GATA3-mediated activation are shown in Table 4.
Discussion
The TCF7L2 transcription factor has been linked to a vari-
ety of human diseases such as type 2 diabetes and cancer
[3,7-9,35]. To investigate the mechanisms by which this
site-specific DNA binding transcriptional regulator can
impact on such diverse diseases, we performed ChIP-seq
analysis for TCF7L2 in 6 different human cell lines, identi-
fying more than 116,000 non-redundant binding sites,
with only 1,864 sites being common to all 6 cell types.
Several striking discoveries that came from our ChIP-seq
analysis of the 6 different cell lines are: i) TCF7L2 has
multiple binding sites near each target gene; ii) TCF7L2
has developed cell type-specific mechanisms for regulating
a set of approximately 14,000 genes; iii) TCF7L2 binds to
more than 40% of the active enhancers in each of the 6
cancer cell lines; and iv) TCF7L2 functions as repressor
when recruited to the genome via tethering by the master
regulator GATA3.
By analysis of the TCF7L2 ChIP-seq datasets from 6
different human cancer cell lines, we identified 116,270
TCF7L2 binding sites, with each cell type having approxi-
mately 25,000 to 50,000 TCF7L2 peaks. We note that
another group has examined TCF7L2 binding in human
HCT116 cells [12], identifying only 1,095 binding sites. It
is not clear why Zhao and colleagues [12] identified such
smaller numbers of TCF7L2 binding sites in HCT116
Frietze et al. Genome Biology 2012, 13:R52
http://genomebiology.com/content/13/9/R52
Page 11 of 18
cells, but it is not likely due to the antibody specificity
(the antibodies used in both studies give similar patterns
on western blots). It is more likely that the 30-fold differ-
ence in peak number is due to the ChIP protocol. Zhao
et al. [12] used protein A agarose beads, whereas we used
magnetic protein A/G beads; we have found that protein
A agarose beads produce low signals in many ChIP assays
(unpublished data). Interestingly, the 116,270 TCF7L2
Figure 7 Transcriptional regulation of TCF7L2 and GATA3 target genes. (a) The nearest gene to each TCF7L2 binding site and the nearest
gene to each GATA3 binding site was identified and the two lists were compared to identify 3,614 genes that are potentially regulated by both
GATA3 and TCF7L2. (b) The expression of the 3,614 GATA3+TCF7L2 bound genes was analyzed in control cells, cells treated with siRNAs to
TCF7L2, and cells treated with siRNAs to GATA3; the number of genes whose expression increases or decreases is shown. (c) A scatterplot of
expression data from RNA-seq experiments. Each point corresponds to one NCBI Reference Sequence (RefSeq) transcript with fragments per
kilobase of gene per million reads (FPKM) values for control and siGATA3 or control and siTCF7L2 knockdown samples shown on a log10 scale.
The dashed line represents no change in gene expression between the two samples. Differentially expressed genes whose function corresponds
to Gene Ontology categories of breast cancer, cell differentiation, and response to hormone stimulus are highlighted.
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binding sites that we identified correspond to only 14,193
genes, with each target gene having an average of 8.2
TCF7L2 binding sites. Many of these binding sites are
cell type-specific, as exemplified by the fact that there are
only three to four TCF7L2 binding sites per target gene
in any one cell type (Figure 2c).
Cell type-specific binding patterns suggest that TCF7L2
binds cooperatively to the genome along with cell type-
specific factors. For example, the AP1 (activator protein 1)
motif is enriched in the sets of HCT116-specific and
MCF7-specific TCF7L2 binding sites. Interestingly,
TCF7L2 has previously been shown to physically interact
with JUN (which is one of the heterodimeric components
of AP1) and it has been suggested that the JUN and
TCF7L2 interaction is a molecular mechanism that inte-
grates the activation of the TCF and CTNNB1 pathway by
the JNK (Jun N-terminal kinase) pathway [36]. Although
ChIP-seq data for AP1 components is not available for
HCT116 or MCF7 cells, there are 7,400 genomic locations
that are bound by TCF7L2 in HCT116 cells that are also
bound by JUN in HeLa cells [11]; it is likely that a much
larger number of co-localizing regions would be identified
if the datasets were from the same cell type. Our detailed
bioinformatic analysis of the HepG2-specific TCF7L2
peaks suggested that HNF4a and FOXA2 might be bind-
ing partners of TCF7L2 in this cell type. A previous study
had shown that FOXA2 and HNF4a colocalize at a subset
of sites in mouse liver [37], but that study did not examine
the relationship of these sites with TCF7L2 binding.
Therefore, we experimentally validated our bioinformatic
prediction by comparing ChIP-seq data for all three fac-
tors. We found that greater than 50% of the TCF7L2
HepG2-specific binding sites are also bound by the liver
transcription factors HNF4a and FOXA2, suggesting that
this trio of factors cooperate in gene regulation. Based on
the identification of motifs for all three factors in the
TCF7L2 peaks, we suggest that TCF7L2, HNF4a, and
FOXA2 all bind directly to the DNA, perhaps with the
liver-specific factors helping to stabilize TCF7L2 genomic
binding to particular enhancer regions in HepG2 cells.
HNF4a and FOXA2 have been shown to be critical deter-
minants of hepatocyte identity; Hnf4a plus Foxa1, Foxa2,
or Foxa3 can convert mouse embryonic and adult fibro-
blasts into cells that closely resemble hepatocytes in vitro
[38]. The induced hepatocyte-like cells had multiple hepa-
tocyte-specific features and reconstituted damaged hepatic
tissues after transplantation. Future studies should address
a potential role of TCF7L2 in hepatocyte identity.
Bioinformatic analysis of the MCF7-specific TCF7L2
sites revealed that the GATA3 motif was highly enriched
and experimental analysis of MCF7 GATA3 ChIP-seq
data showed that nearly one-half of the MCF7-specific
TCF7L2 binding sites co-localize with GATA3. Interest-
ingly, we found that the TCF7L2 motif was not enriched
in the regions bound by both TCF7L2 and GATA3. These
results suggested that perhaps GATA3 binds directly to
the DNA at these sites and tethers TCF7L2 to the genome
at the MCF7-specific TCF7L2 binding sites Accordingly,
we showed that depletion of GATA3 reduced recruitment
of TCF7L2 to a subset of genomic sites. We also demon-
strated that TCF7L2 functions mainly as a repressor when
tethered to the genome via GATA3. At some genes,
TCF7L2 cooperatively represses genes with GATA3 but at
other genes TCF7L2 antagonizes GATA3-mediated activa-
tion (Figure 8).
Specification of cell phenotypes is achieved by sets of
master transcriptional regulators that activate the genes
specific for one cell fate while repressing genes that specify
other cell fates. The GATA factors, which include six site-
specific DNA binding proteins that bind to the sequence
(A/T)GATA(A/G), are master regulators that govern cell
differentiation [39-44]. For example, GATA1-3 have been
linked to the specification of different hematopoietic cell
fates and GATA4-6 are involved in differentiation of car-
diac and lung tissues. Also, GATA3 is the most highly
enriched transcription factor in the mammary epithelium,
has been shown to be necessary for mammary cell differ-
entiation, and is specifically required to maintain the lumi-
nal cell fate [43,44]. Studies of human breast cancers have
shown that GATA3 is expressed in early stage, well-differ-
entiated tumors but not in advanced invasive cancers. In
addition, GATA3 expression is correlated with longer dis-
ease-free survival and evidence suggests that it can prevent
or reverse the epithelial to mesenchymal transition that is
characteristic of cancer metastasis [45]. Our studies show
that TCF7L2 cooperates with the master regulator
GATA3 to repress transcription in the well-differentiated
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MCF7 breast cancer cell line and suggest that a TCF7L2-
GATA3 complex may be a critical regulator of breast cell
differentiation.
Our finding that TCF7L2 co-localizes and cooperates in
gene regulation with a GATA factor in MCF7 breast
cancer cells is similar to a recent study of TCF7L2 in
hematopoietic cells. Trompouki et al. [13] showed that in
hematopoietic cells, TCF7L2 co-occupies sites with
GATA1 and GATA2, which are master regulators of
blood cell differentiation. Both the TCF7L2 motif and the
GATA motif were found at the co-bound sites (suggesting
adjacent binding of the two factors, not tethering) and
TCF7L2 functioned as a transcriptional activator at those
sites. In contrast, our studies indicate that co-localization
of TCF7L2 with GATA3 in MCF7 cells is not due to
adjacent binding but rather TCF7L2 is tethered to the gen-
ome by interaction with GATA3 binding to a GATA motif
and that this tethering results in transcriptional repression.
A study of Drosophila TCF binding to the Ugt36Bc
upstream region indicated that TCF represses transcrip-
tion of the Ugt36Bc gene by binding to non-traditional
TCF motifs [46]. Interestingly, the three Ugt36Bc TCF
sites (AGAAAT, AGATAA, AGATAA) are almost identi-
cal to the GATA3 motif. Blauwkamp et al. [46] suggest
that the sequence to which TCF binds has an important
function in determining whether a gene will be activated
or repressed. Their studies did not address whether TCF
bound directly to the GATA-like motifs. However, based
on our studies, it would be worthwhile to investigate a
possible genomic tethering mechanism of TCF by GATA
factors in Drosophila.
Conclusions
Our studies reveal numerous new insights into TCF7L2-
mediated gene regulation and suggest that TCF7L2 coop-
erates with other site-specific DNA binding factors to
regulate transcription in a cell type-specific manner. Speci-
fically, we show that TCF7L2 has highly cell type-specific
binding patterns, co-localizes with different factors in
different cell types, and can be tethered to the DNA by
GATA3 in breast cancer cells. Our work, in combination
with other studies [13,47], suggests that TCF7L2 may play
a critical role in creating and maintaining differentiated
phenotypes by cooperating with cell type-specific master
regulators such as HNF4a and FOXA2 in liver cells and
GATA3 in breast cells. Both FOXA and GATA family
members have been classified as pioneer factors, that is,
transcription factors that can access their binding sites
when other factors cannot, helping to create open chro-
matin to enable subsequent binding of other factors [48].
It is possible that FOXA2 and GATA3 serve as pioneer
factors that enhance the ability of TCF7L2 to access its
sites in liver and breast cells. In addition to having cell
type-specific partners, there are many different isoforms of
TCF7L2. Although the major isoforms of TCF7L2 are
similar in most cell types, it is possible that minor isoforms
contribute to the cell type-specificity of TCF7L2 binding
via interaction of co-localizing proteins with alternatively
Figure 8 Two modes of TCF7L2-mediated transcriptional repression of GATA3 target genes. (a) GATA3 tethers TCF7L2 to the genome
and both factors cooperate to repress target genes. (b) GATA3 tethers TCF7L2 to the genome with TCF7L2 antagonizing GATA3-mediated
transcriptional activation.
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encoded exons of TCF7L2. We anticipate that future stu-
dies employing isoform-specific antibodies to identify
TCF7L2 binding sites in normal and diseased tissues will
provide additional insight into the transcriptional net-
works that are altered in diseases such as type 2 diabetes,
pancreatic cancer, and coronary artery disease.
Materials and methods
Cell culture
The human cell lines HCT116 (ATCC #CCL-247), HepG2
(ATCC # HB-8065), HEK293 (ATCC #CRL-1573), MCF7
(ATCC #HTB-22), HeLa (ATCC #CCL-2.) and PANC1
(ATCC #CRL-1469) were obtained from the American
Type Culture Collection. HCT116 cells were grown in
McCoy’s 5A Medium supplemented with 10% fetal bovine
serum and 1% penicillin/streptomycin until 80% confluent,
whereas HepG2, HEK293, MCF7, HeLa and PANC1 cells
were grown in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% fetal bovine serum, 2 mM L-gluta-
mine and 1% penicillin/streptomycin) until 75 to 90%
confluent.
siRNA-mediated knockdown
All siRNAs were purchased from Dharmacon (Thermo
Fisher Scientific-Dharmacon Products, Lafayette, CO,
USA; ON-TARGET plus SMART pool - Human GATA3,
TCF7L2 and Non-Targeting siRNA) and transfected using
Lipofectamine™ 2000 Transfection Reagent according to
the manufacturer’s instructions (Life Technologies, Grand
Island, NY, USA). Then, 48 to 56 h following transfection,
cells were either crosslinked for ChIP assays or collected
for RNA and protein extraction.
ChIP-seq assays
The antibodies used for ChIP-seq were: TCF7L2 (Cell Sig-
naling Technology, Danvers, MA, USA; C48H11 #2569),
GATA3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA;
#sc-268), H3K4me1 (Cell Signaling Technology, Danvers,
MA, USA; 9723S lot1), and H3K27Ac (Abcam, Cam-
bridge, MA, USA; Ab4729 lot #GR16377-1). The TCF7L2
antibody will detect both major isoforms of TCF7L2. See
Additional file 2 for details of all ChIP-seq experiments.
For all factor or histone modification and cell type combi-
nation, we performed duplicate ChIP-seq experiments
using chromatin from two different cell culture dates. For
the TCF7L2 ChIP-seq assays, 500 μg chromatin was incu-
bated with 25 μg of antibody; for the GATA3 experiments,
600 μg chromatin was incubated with 50 μg of antibody;
and for the histone ChIP-seq experiments, 10 to 12 μg
chromatin and 8 to 10 μg of antibody were used. TCF7L2
and histone ChIP assays were performed as described pre-
viously [49] using protein A/G magnetic beads to collect
the immunoprecipitates. GATA3 ChIP-seq experiments
were performed using StaphA (Sigma-Aldrich, St. Louis,
MO, USA) to collect the immunoprecipitates [50]. After
qPCR confirmed enrichment of target sequences in ChIP
versus input samples, libraries were created as previously
described with minor modifications [49]. Gel size selection
of the 200 to 500 bp fraction (TCF7L2 and histones) or
the 300 to 600 bp fraction (GATA3) was conducted after
the adapter ligation step, followed by 15 amplification
cycles. qPCR (see Additional file 17 for a list of primers
used in this study) was performed to confirm enrichment
of targets in the libraries and then the libraries were ana-
lyzed using an Illumina GAIIx. Sequence reads were
aligned to the UCSC human genome assembly HG19
using the Eland pipeline (Illumina).
ChIP-seq data processing
The BELT program [24] and Sole-search [11,51] were
used to identify peaks for TCF7L2 and for modified his-
tones. We used the ENCODE overlap rules to evaluate the
reproducibility of the two biological replicates for each fac-
tor or histone modification and cell-type combination. For
this, we first truncated the peak lists of the two replicates
for a given factor/cell-type combination so that both the A
and B replicate peak list were the same length. Then, we
overlapped the top 40% of the replicate A peak list with
the entire replicate B peak list (and vice versa). ENCODE
standards state that approximately 80% of the top 40% set
should be contained in the larger set. After determining
that replicate datasets met this standard (Additional file 4),
we merged the two replicates and called peaks on the
merged dataset. To determine if we had identified the
majority of the TCF7L2 peaks in each cell type, we per-
formed a saturation analysis. We randomly selected differ-
ent percentages of the reads (10%, 20%, 30%,...,100%) from
the merged datasets from the TCF7L2 ChIP-seq experi-
ments for each cell line and called peaks using the BELT
program; each merged dataset was analyzed three times.
The number of peaks identified in each subset of the total
reads was plotted to demonstrate that we had enough
reads for each dataset to identify the majority of peaks
(Additional file 7).
RNA-seq
RNA was extracted using Trizol Reagent (Life Technolo-
gies) following the suggested protocol; 2 μg of each RNA
sample was used with the Illumina TruSeq RNA Sample
Prep Kit (catalogue number RS-122-2001) to make RNA
libraries following the Illumina TruSeq RNA Sample pre-
paration Low-Throughput protocol. Briefly, RNA was
fragmented, then first-strand cDNA was prepared using
the kit-supplied 1st Strand Master Mix and user-supplied
Superscript III (Life Technologies, catalogue number
18080-051) followed by second strand cDNA synthesis.
The Illumina protocol and reagents were used to com-
plete the library preparation, with 12 cycles of PCR
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amplification. Libraries were sequenced using an Illumina
GAIIx and analyzed as described in Additional file 3.
ChIP-qPCR assays
ChIP assays were performed as described in the ChIP-seq
section, except that 30 μg equivalents of DNA was used
for each ChIP reaction. The ChIP eluates were analyzed
by qPCR using the Bio-Rad SsoFast™ EvaGreen® Super-
mix (catalogue number 172-5202) according to the manu-
facturer’s instructions (Bio-Rad, Hercules, CA, USA).
Generation of TCF7L2 expression constructs and co-
immunoprecipitation assays
TCF7L2 expression constructs were generated by PCR
amplification of cDNA prepared from RNA isolated
from MCF7 cell cultures and used for GATEWAY clon-
ing into the pTRED-N-FLAG expression vector, which
contains an amino-terminal FLAG tag. Control empty
vector or an expression construct was transfected into
MCF7 cells using Lipofectamine™ 2000 according to
the manufacturer’s instructions (Life Technologies); 36 h
following transfection, cells were harvested and lysed in
ice-cold NP-40 lysis buffer (phosphate-buffered saline,
0.25% NP-40, 0.1% sodium-deoxycholate, 2 mM phenyl-
methylsulfonyl fluoride (PMSF) and 10 μg/ml leupeptin
and aprotinin) for co-immunoprecipitation assays. Fol-
lowing extraction on ice for 30 minutes and clarification
by centrifugation, soluble protein extracts were diluted
1:10 with lysis buffer and incubated with either an anti-
FLAG M2 agarose conjugated antibody (Sigma catalogue
number A2220), an anti-GATA3 conjugated antibody
(Santa Cruz HG3-31-AC), or a control rabbit IgG agar-
ose conjugated antibody (Sigma catalogue number
A2909) for 4 hours at 4°C. The beads were then washed
four times and eluted with SDS-PAGE sample buffer
prior to SDS-PAGE and western blot analysis using anti-
bodies specific for GATA3 (Santa Cruz HG3-31) or
FLAG (Sigma catalogue number A8592).
Data access
All data are publicly available via the UCSC Genome
Preview Browser and/or has been submitted to the
Gene Expression Omnibus (information concerning how
to access the data is provided in Additional file 2).
Additional material
Additional file 1: Figure S1 - antibody validation.
Additional file 2: Table S1 - summary of ChIP-seq and RNA-seq
experiments. All ChIP-seq experiments performed by the Farnham
laboratory are listed; GEO numbers are provided and the data are
availableat the UCSC genome browser
Additional file 3: Supplementary Methods.
Additional file 4: Table S2 - ChIP-seq reproducibility. To determine
the reproducibility of the ChIP-seq data, we used the method of
evaluating replicates as described in the ENCODE Standards document
[53]. Briefly, the ENCODE consortium rules are as follows: ‘80% of the top
40% of the targets identified in one replicate should be contained within
the list of targets from the other replicate’. This metric was chosen based
on experiences of all the ENCODE production groups to allow an
achievable threshold of reproducibility while producing high quality
target lists. All ChIP-seq data for site-specific factors submitted to the
UCSC browser as part of ENCODE have to pass this quality metric and, as
can be seen in Table S2, all of the TCF7L2 data in our manuscript have
passed. We note that the metric for reproducibility of ‘broad peak’
histone marks (such as H3K4me1) has not yet been established by
ENCODE. Due to difficulties in calling peaks for such histone marks, the
overlap is sometimes lower than 80%.
Additional file 5: Table S3 - all TCF7L2 peaks in six cell types.
TCF7L2 peaks were called using BELT [54] and the merged datasets for
each cell type (see Additional file 4 for the peak calling parameters for
each dataset).
Additional file 6: Table S7 - summary of TCF7L2 peak
characteristics. TCF7L2 peaks were called using BELT [54] and the
merged datasets for each cell type (see Additional file 4 for the peak
calling parameters for each dataset).
Additional file 7: Figure S2 - saturation analysis.
Additional file 8: Table S9 - amplified regions in the six cancer cell
lines. Sole-search was used to call peaks for TCF7L2 in each of the six
cancer cell lines, using input from each line as the specific control. One
novel feature of Sole-search is that it provides a list of all amplified
regions found in the input control. For each cancer cell line, a worksheet
of all amplified regions is provided; column F indicates the fold
amplification and column I indicates the chromosomal coordinates of
the amplified region
Additional file 9: Table S10 - TCF7L2 peaks in amplified regions. The
TCF7L2 peaks from each cell line were overlapped with the amplified
regions from that same cell line. Presented in this table is a summary of
all the overlaps and a worksheet for each cell line that lists each peak
that is found in the amplified regions (column A indicates the
chromosome and columns D and E indicate the chromosomal
coordinates of the amplified region that contains the peak; column F
indicates the fold amplification of the amplified region; and column I
indicates the chromosomal coordinate of the TCF7L2 peak and the
height of the peak).
Additional file 10: Table S4 - TCF7L2 peaks unique to each of the
six cell types. To identify cell type-specific TCF7L2 peaks for a particular
cell, we first combined the five sets of peaks from the other cell types,
and then identified the unique set of peaks for the given cell type by
removing sites in common with the combined set. For these analyses,
the merged replicate TCF7L2 datasets were used.
Additional file 11: Figure S3 - ChIP-qPCR validation of TCF7L2 sites.
Additional file 12: Figure S4 - TCF7L2 binds to cell type-specific
enhancer regions.
Additional file 13: Table S6 - TCF7L2 binding motifs in six cell
types. We used our ChIPMotifs program to identify two canonical
TCF7L2 motifs, W1 of 6 bp and W2 of 8 bp, for each cell type. We then
used each of two motifs’ position weight matrices to scan the sequences
of the peaks to determine how many peaks contained the motifs; we
examined the set of all peaks and the set of cell type-specific peaks for
all six cell types.
Additional file 14: Figure S5 - motif recovery percentage plots.
Additional file 15: Figure S6 - Re-ChIP analysis of GATA3 and
TCF7L2 sites.
Additional file 16: Table S8 - RNA-seq analysis of TCF7L2 and
GATA3 knockdowns. The RNAseq data were processed by TopHat and
Cufflinks programs essentially as described [55].
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Additional file 17: Table S5 - primers used in ChIP-qPCR analyses.
The sequences of positive and negative control primers used for ChIP-
qPCR.
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